Focal adhesion kinase (FAK) is a novel “stromal”-related therapeutic target as a major signaling molecule, highly expressed in MCL, that functions downstream of integrins (including CXCL12) and that translates signals from the extracellular matrix in the bone marrow. Here, CXCL12 is linked to mantle cell lymphoma.